Therefore, upstream inhibition, at the level of Src or EGFR, appears to be more effective than blockade of the individual downstream pathways involving ERK1/2, PI3Kδ/Akt or the transcriptional factor NFκB – a finding that may have important clinical implications in the treatment of asthma. The gene discussed is MAPK3; the disease is asthma.